Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361172 | 0.81 | S1PR4 (0.40) | CYP11B1CYP11B2ALDH1A1LMNA | |
| SCHEMBL30499195 | 0.80 | CYP11B1 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL25291420 | 0.80 | CYP11B1 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL12042082 | 0.79 | KDM4E (0.40) | CYP11B1CYP11B2LMNA | |
| SCHEMBL29130957 | 0.78 | HSD17B10 (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL30602388 | 0.78 | HSD17B10 (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL2716190 | 0.76 | CYP11B1 (0.51) | CYP11B1CYP11B2CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL487518 | 0.76 | CYP11B1 (0.51) | CYP11B1CYP11B2CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL28392432 | 0.75 | ALDH1A1 (0.48) | CYP11B1CYP11B2ALDH1A1LMNA | |
| SCHEMBL487778 | 0.75 | CYP11B1 (0.50) | CYP11B1CYP11B2CHRNB2CHRNA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4673436-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024179948-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | PKN3, PKMYT1, IP6K3 | CYP11B1 1496/4885CYP11B2 2071/4885CHRNB2 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.